Extract
The burden and societal impact of obstructive sleep apnoea (OSA) needs to be more widely understood to guide health policies and improve value-based care. OSA affects one billion people worldwide, representing a major and still under-recognised health problem. Its prevalence is expected to continue to increase, owing to the obesity epidemic and the increase in life expectancy [1]. OSA has been associated with numerous long-term consequences, including cardiovascular and metabolic disorders, and neuropsychiatric diseases [2–4]. Also, OSA impairs quality of life, cognitive function, and productivity in the workplace, and causes road traffic accidents, resulting in injuries and fatalities [5].
Abstract
The reported effect of CPAP on cardiovascular outcomes in sleep apnoea should be interpreted with caution and several factors must be considered before definite conclusions can be drawn https://bit.ly/3lLQG4d
Footnotes
Conflict of Interest: S. Schiza has nothing to disclose.
Conflict of interest: P. Lévy has nothing to disclose.
Conflict of interest: M.A. Martinez-Garcia has nothing to disclose.
Conflict of interest: J-L. Pépin reports grants and research funds from (payment made to institution) Air Liquide Foundation, Agiradom, AstraZeneca, Fisher and Paykel, Mutualia, Philips, Resmed and Vitalaire; consulting fees from Agiradom, AstraZeneca, Boehringer Ingelheim, Jazz Pharmaceutical, Night Balance, Philips, Resmed and Sefam.
Conflict of interest: A. Simonds has nothing to disclose.
Conflict of interest: W. Randerath reports personal fees for lectures from Weinmann, Heinen & Löwenstein, Resmed, Inspire, Philips Respironics, Bioprojet and Vanda Pharma; personal fees for travel from Heinen & Löwenstein, Resmed, Inspire, Philips Respironics and Bioprojet.
- Received July 13, 2021.
- Accepted July 30, 2021.
- Copyright ©The authors 2021. For reproduction rights and permissions contact permissions{at}ersnet.org